Association of Vascular Endothelial Growth Factor (VEGF) serum levels And Ankylosing Spondylitis in Egyptian patients
Not Applicable
Recruiting
- Conditions
- Ankylosing spondylitis
- Registration Number
- PACTR202210522771809
- Lead Sponsor
- Hossam salaheldin Abdelmohsen Labib
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Adult AS(ankylosing spondylitis ) patients
20-60 years old
met the modified New York criteria for AS.
Exclusion Criteria
Patients with any associated rheumatic diseases.
- patients with cancers.
- Diabetic patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the role of VEGF in the pathogenesis of ankylosing spondylitis among Egyptian patients?
How do VEGF serum levels correlate with disease activity markers in ankylosing spondylitis?
Can VEGF serve as a biomarker for predicting treatment response in ankylosing spondylitis?
What are the potential adverse effects of VEGF-targeted therapies in autoimmune conditions?
How does VEGF inhibition compare to TNF-alpha blockers in managing ankylosing spondylitis?